Subscribe to this Blog

Blog Archive

Subscribe Via Email

Enter your email address:

Tuesday, December 12, 2006

Johnson & Johnson subsidiary halts trial due to trial distribution issues

Centocor Inc., a subsidiary of Johnson & Johnson anounced that it had halted the distribution of an experimental trial drug for arthritis.  Distribution problems getting the product to trial test sites were cited as the reason behind the temporary halt.

A Centocor spokesman, Michael Parks, took the action after Centocor's distributor was not able to distribute the product, currently named golimumab, to approximately 15% of locations designated for the trial.  This is supposed to be a temporary halt resulting from a "temporary" distribution issue.  The Centocor distributor has not been identified as of yet.

Note. This test area was identified as being in the United States.  Schering Canada, Inc. is the Centocor distributor in Canada.